• Home Dutch
  •  EN 
  • Employee login

Former Hospital and Clinical Pharmacy

Print 
  1. Vu DH, Koster RA, Wessels AM, Greijdanus B, Alffenaar JW, Uges DR. Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Feb 15; 917-918: 1-4.
  2. Bertholee D, ter Horst PGJ, Hijmering ML, Spanjersberg AJ, Hospes W,  Wilffert B. Blood concentrations of cefuroxime in cardiopulmonary bypass surgery. Int J Clin Pharm 2013;35(5): 798-804
  3. Knol W, van Marum R, Jansen PAF, Strengman E, Al Hadithy AFY, Wilffert B, Schobben AF, Ophoff RA, Egberts TC. Genetic variation and the risk of haloperidol related parkinsonism in elderly patients: a candidate gene approach.J Clin Psychopharmacol  2013; 33(3): 405-410.
  4. De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J. 2013 Jun; 41(6): 1386-92.
  5. Yska JP, van der Linde S, Tapper VV, Apers JA, Emous M, Totté ER, Wilffert B, van Roon EN. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes.. Obesity Surgery 2013; 23(6): 819-825.
  6. Golestani R, Zeebregts CJ, Terwisscha van Scheltinga AG, Lub-deHooge MN, van Dam GM, Glaudemans AW, Dierckx RA, Suurmeijer AJ, Boersma HH, Nagengast WB, Slart RH. Geasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography. Mol Imaging 2013 Jun 1; 12(4): 235-43.
  7. Oude Munnik TH, Tamas KR, Lub-de Hooge MN, Vedelaar SR, Timmer-Bosscha H, Walenkamp AM, Weidner KM, Hering F, Tessier J, de Vries EG. Placental growth factor (PIGF)-specific uptake in tumor microenvironment of 89Zr-labeled PIGF antibody RO5323441. J Nucl Med 2013 Jun; 54(6): 929-35.
  8. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schröder CP, de Vries EG. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013 Jun 1; 73(11): 3347-55.
  9. Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB; International Group for the study of Linezolid. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J. 2013 Jul; 42(1): 288-90.
  10. Akkerman O, Pranger A, van Altena R, van der Werf T, Alffenaar JW. Rifampicin and moxifloxacin for tuberculous meningitis. Lancet Infect Dis. 2013 Jul;13(7):568-9.
  11. Gaykema SB, Brouwers AH, Lub-deHooge MN, Pleijhuis RG, Timmer Bosscha H, Pot L, van Dam GM, van der Meulen SB, de Jong JR, Bart J, de Vries J, Jansen L, de Vries EG, Schröder CP. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med 2013 Jul; 54(7): 1014-8.
  12. Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multi-resistant tuberculosis. Antimicrob Agents Chemother 2013 Aug; 57 (8): 3676-80.
  13. Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J. 2013 Aug; 42 (2): 504-12.
  14. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH; RAVE-ITN Research Group. Efficacy of remision-indution regimens for ANCA-associated vasculitis. N Engl J Med 2013 Aug 1;369 (5): 417-27.
  15. Alsaad N, Wilffert B, van Altena R, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. Potential antimicrobial agents for the treatment of MDR-TB. Eur Respir J 2013 Aug 29. [Epub ahead of print].
  16. Bult W, Kroeze SG, Elschot M, Seevinck PR, Beekman FJ, de Jong HW, Uges DR, Kosterink JG, Luijten  PR, Hennink WE, van het Schip AD,  Bosch JL, Nijsen JF, Jans JJ. Intratumoral administration of holmium-166 acetylacetonate microspheres; antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One 2013; 8(1): e52178.
  17. Dalbøge CS, Nielsen XC, Dalhoff K, Alffenaar JW, Duno M, Buchard A, Uges DR, Jensen AG, Jürgens G, Pressler T, Johansen HK, Høiby N. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2013 Sep 10. pii: S1569-1993(13)00145-8.
  18. Magis-Escurra C, Alffenaar JW, Hoefnagels I, Dekhuijzen PN, Boeree MJ, van Ingen J, Aarnoutse RE. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. Int J Antimicrob Agents. 2013 Sep;42(3):256-61.
  19. Van der Elst KC, Span LF, van Hateren K, Vermeulen KM, van der Werf TS, Greijdanus B, Kosterink JG, Uges DR, Alffenaar JW. Dried blood spot analysis for therapeutic drug monitoring of voriconazole, fluconazole en posaconazole. Antimicrob Agents Chemother. 2013 Oct; 57 (10): 49999-5004.
  20. Van Wanrooy MJ, Rodgers MG, Uges DR, Arends JP Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar. Low but sufficient anidulafungin exposure in critcally ill patients. Antimicrob Agenst Chemother. 2013 Oct 28 [Epub ahead of print].
  21. Alghanem S, Paterson I, Touw DJ, Thomson AH. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. J Antimicrob Chemother 2013; doi: 10.1093/jac/dkt035.
  22. Geerlings CJ, de Man P, Rietveld AP, Touw DJ, Cohen Tervaert JW. A practical thrice weekly Ertapenem dosage regime for chronic hemodialysis patients? Clin Nephrol. 2013 Oct;80(4):312.
  23. Ananias HJ, Yu Z, Hoving HD, Rosati S, Dierckx RA, Wang F, Yan Y, Chen X, Pruim J, Lub-de Hooge MN, Helfrich W, Elsinga PH, de Jong IJ. Application of (99m)Technetium-HYNIC (tricine/TPPTS)-Aca-Bombesin (7-14) SPECT/CT in prostate cancer patients; a first-in-man study. Nucl Med Biol 2013 Oct;  40(7):933-8.
  24. Kijanka M, Warnders FJ, El Khattabi M, Lub-de Hooge M, van Dam GM, Ntziachristos V, de Vries L, Oliveira S, van Betgen Een Henegouwen PM. Rapid optical Imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800 CW for image-guided surgery. Eur J Nucl Med Mol Imaging 2013 Oct; 40(11): 1718-29.
  25. Alsaad N, van der Laan T, van Altena R, Wilting KR, van der Werf TS, Stienstra Y, van Soolingen D, Alffenaar JW. Trimethoprim/sulfamethoxazole susceptibility of Mycobacterium tuberculosis. Int J Antimicrob Agents. 2013 Nov;42(5):472-4.
  26. Maurer JM, Schellekens RC, van Rieke HM, Stellaard F, Wutzke KD, Buurman DJ, Dijkstra G, Woerdenbag HJ, Frijlink HW, Kosterink JG. ColoPulse tablets perform comparably in healthy volunteers and Crohn’s patients and show no influence of food and time of food intake on bioavailability. J Control Release 2013 Dec 28; 172(3): 618-24.
  27. Maurer JM, Schellekens RCA, Wutzke KD, Stellaard FS Isotope-labelled urea to test colon drug delivery devices in vivo: principles, calculations and interpretations. IEHS 2013 ;49(4): 473-491
  28. Bolhuis MS, Altena RV, Soolingen DV, Lange WC, Uges DR, Werf TS, Kosterink JG, Alffenaar JW. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J. 2013 Dec; 42(6): 1614-21.
  29. Akkerman OW, van Altena R, Klinkenberg T, Brouwers AH, Bongaerts AH, van der Werf TS, Alffenaar JW. Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J. 2013 Dec;42(6):1750-2.
  30. van Wanrooy MJ, Santoe RN, van der Elst KC, Wilmer CM, van Hateren K, Wessels AM, Greijdanus B, Alffenaar JW, Uges DR. Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method. Ther Drug Monit. 2013 Dec; 35(6): 778-84.
  31. Mas-Morey P, Visser MHM, Winkelmolen L, Touw DJ. Clinical Toxicology and Management of Intoxications With Synthetic Cathinones (''Bath Salts''). J Pharm Pract 2013; 26: 353-257
  32. Buurman DJ, Van de Casteele N, Sturkenboom MG, Kleibeuker JH, Vermeire S, van der Kleij D, Rispens T, Gils A, Dijkstra G. Letter detection of infliximab levels and anti infliximab antibodies comparison of three different assays, authors reply. Aliment Pharmacol Ther 2013; 37: 282 (IF 3 769).
  33. Berm EJJ, Risselada AJ, Mulder H, Hak E, Wilffert B. Letter to the Editor: Phenoconversion of cytochrome P450 2D6: The need for identifying the intermediate metabolizer genotype. J Clin Psychiatry 2013; 74: 10.
  34. R.V.C. Buijs, T.P.Willems, R.A. Tio, H.H. Boersma I.F.J. Tielliu, R.H.J.A. Slart, C. J. Zeebregts. Calcification as a Risk Factor for Rupture of Abdominal Aortic Aneurysm. Eur J Vasc 2013; 46: 542-8.
  35. L.E..Juárez Orozco, J.Glauche, E Alexanderson, C. J. Zeebregts, H.H. Boersma, A.W.J.M. Glaudemans, R.A. Dierckx, D.J. van Veldhuisen, R.A. Tio, R.H.J.A. Slart. Myocardial perfusion reserve in spared myocardium: correlation with infarct size and left ventricular ejection fraction EJNMMI 2013 40:1148-54
  36. R.V.C. Buijs, T.P.Willems, R.A. Tio, H.H. Boersma I.F.J. Tielliu, R.H.J.A. Slart, C. J. Zeebregts. Current state of experimental imaging modalities for risk assessment of abdominal aortic aneurysm J Vasc Surg 2013, 57(3):851-9.
  37. Boekhoofdstuk: E.L. van der Veen, H.J. de Haas, A.D. Petrov,  C.P.M. Reutelingsperger,  J.G.W. Kosterink, C.J. Zeebregts, R.A. Tio, R.H.J.A. Slart,  H. H. Boersma. The story of myocardial infarction: before, when it strikes, and afterwards: a tale in images . In: SPECT: Technology, Procedures and Applications.Nova Scientific Publishers, 2013. Editors: Hojjat Ahmadzadehfar and Elham Habibi, pp 159-187
  38. H. Meurs, B.G.J. Dekkers, H. Maarsingh, A.J. Halayko, J. Zaagsma, R. Gosens. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013, 26(1):145-55.
  39. D.B. Wright, T. Trian, S. Siddiqui, C.D. Pascoe, O.O. Ojo, J.R. Johnson, B.G.J. Dekkers, S. Dakshinamurti, R. Bagchi, J.K. Burgess, V. Kanabar V. Functional phenotype of airway myocytes from asthmatic airways. Pulm Pharmacol Ther. 2013, 26(1):95-104.
  40. D.B. Wright, T. Trian, S. Siddiqui, C.D. Pascoe, J.R. Johnson, B.G.J. Dekkers, S. Dakshinamurti, R. Bagchi, J.K. Burgess, V. Kanabar, O.O. Ojo. Phenotype modulation of airway smooth muscle in asthma. Pulm Pharmacol Ther. 2013, 26(1):42-9.
  41. B.G.J. Dekkers, K. Racké, M. Schmidt. Distinct PKA and Epac compartmentalization in airway function and plasticity. Pharmacol Ther. 2013, 137(2):248-65.
  42. T.A. Oenema, G. Mensink, L. Smedinga, A.J. Halayko, J. Zaagsma, H. Meurs, R. Gosens, B.G.J. Dekkers.Cross-talk between transforming growth factor-β1 and muscarinic M2 receptors augments airway smooth muscle proliferation. Am J Respir Cell Mol Biol. 2013, 49(1):18-27.
  43. B.G.J. Dekkers, A.I.R. Spanjer, R.D. van der Schuyt, W.J. Kuik, J. Zaagsma, H. Meurs. Focal adhesion kinase regulates collagen I-induced airway smooth muscle phenotype switching.J Pharmacol Exp Ther. 2013, 346(1):86-95.
  44. Raphael MF, den Boer AM, Kollen WJ, Mekelenkamp H, Abbink FC, Kaspers GJ, Zomer-Kooijker K, Molmans BH, Tissing WJ. Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? : Results from a prospective multicenter double blind randomized controlled trial. Support Care Cancer. Epub 2013 Nov 7.
  45. Garcia-Allende PB, Glatz J, Koch M, Tjalma JJ, Hartmans E, Terwisscha van Scheltinga AG, Symvoulidis P, van Dam GM, Nagengast WB, Ntziachristos V. Towards clinically translatable NIR fluorescence molecular guidance for colonoscopy. Biomed Opt Express. 2013 Dec 4;5(1):78-92.